Eugene Consulting Inc.
1602- 111 St. Clair Ave W
Toronto, ONM4V 1N5

October/November 2020 Report
Update on Deep Genomics- Since receiving a $40 million series B round, the company has been identifying new
drug targets across multiple diseases areas- The company has since turned up many more prospects than it can pursue on itsowno Therefore, partnering with other companies has become an essential
component to their business strategy- Brendan Frey, the CEO of Deep Genomics, explains how they had always planned toopen up an office into the biotech hotbed of Boston, and that the pandemic actuallylent a helping hand with thiso New norms around remote work and virtual meetings made it easier for
Deep Genomics to start recruiting there- The company’s work is based on its AI Workbench – a platform made up of about 30
different machine learning systems, combining deep learning, automation, advanced
biomedical knowledge and huge amounts of in vitro and in vivo data
Synex Medical
https://betakit.com/synex-medical-raises-6-99-million-cad-seed-round-for-healthmonitoring-technology/ - Oct. 29, 2020
- Synex Medical is a Toronto-based healthcare startup, which offers a wearable
solution that measures blood metabolites
o The wearable device tells the user how their body is performing bymeasuring the metabolites that affect everything from weight gain to athletic
performance to the likelihood of developing diabetes in real-time- They have raised a $6.99 million CAD seed round of financing
o The seed round was led by Accomplice – a Boston-based seed venture capital
firmo Previous investors: Radical Ventures and angel investor Naval Ravikant alsoparticipatedo This will be used to grow Synex Medical’s team and support the startup’s
expansion to the U.S.
- CEO and co-founder Ben Nashman has stated that they are expanding theiroperations to Boston- The company was founded in 2017 and their technology is based on magnetic
resonance – the same principle used in magnetic resonance imaginingo The technology is aimed to non-invasively and accurately measure critical
blood metabolites like glucose, lactate, and ketones

Eugene Consulting Inc.
1602- 111 St. Clair Ave W
Toronto, ONM4V 1N5

XtalPi- XtalPi is a pharmaceutical technology company that is reinventing the industry’s
approach to drug research and development with its Intelligent Digital Drug
Discovery and Development (ID4) platform
Their Software
XtalForce- XtalForce is a visual force field calculation software that allows you to either use ageneral force field to complete simulations, or obtain force field training set fromquantum mechanics calculations on one’s unique compound library, and train atailor force field suitable for one’s specifical chemical space- Through the visual interface, users can intuitively operate the molecules, and canclick to view the specific parameters corresponding to each term in the molecule- The user can submit a quantum mechanical calculation task to the cloud, call a more
massive computing cluster to shorten the calculation time, and use variable analysis
charts to judge the behavior of the calculation result- The system can connect to the open source database containing millions ofmolecules and thousands of quantum mechanical data
XtalVision- XtalVision is a smart tool for delivering crystal structure prediction reports- All the calculated structures are shown with basic information and 3D visualization- One can click at the data point in the figure to get more information such as crystalstructure, the relative lattice energy, density space group number, cell parameters,and XRD pattern- One can click on the label of the corresponding torsion angle to see the distribution
with a polar coordinate system
Renova- Renova provides platform support for XtalPi AI Research Center (ZARC) and its AI
drug R&D efforts- The platform helps researchers effectively manage projects through graphicalinterface by supporting tools integration, computational process management, teamcollaboration, and other aspects- Systematization facilitates the use of various AI prediction models and visualizationof calculation results, which helps accelerate the discovery of new drugs and avoid
the molecular defects that can only be found in the clinical stage as early as possible- Renova provides various AI models related to new drug discovery, including activity
and ADME/T predictions, new drug scaffold design, new binding pocket discovery,
and the management of associated computational results

Eugene Consulting Inc.
1602- 111 St. Clair Ave W
Toronto, ONM4V 1N5-Renova also provides complete and customizable computing process support,
where users can build customized R&D workflows based on specific needs,
assemble models, and analyze the predicted results
It also provides users with customizable reports to help analyze the results
efficiently and quickly
Renova support teamwork by allowing data sharing with designatedauthentication/authorization and computational results sharing

Key Services- Crustal Structure Prediction – an integrated approach that effectively accelerates
the solid-state research and decision-making process to reduce the overall risk inlate-stage developmento By combing CSP with experimental screening, researchers can judge withgreater confidence whether the current experimental screening is sufficient,verify the purity of the selected crystal powder, and understand the stability
risk of crystal forms obtained in the laboratory- Solid-State Screening and Evaluation – A comprehensive screening that optimizes
patent protection and lifecycle management which increases the long-term value ofa drug- Crystal Structure Determination – XtalPi has developed a crystal structure
analysis technology based on the experimental data and theoretical methods, which
can obtain the 3D structure information of drug solids that are traditionally hard todetermine solely by experimentso With a small amount of solid powder of XRPD spectrum, the 3D structure
information can be easily obtainedo In cases where one has a limited amount of time and material available, thiscomputational analysis could effectively assist in determining the ideal solid
form of the drug candidate for early-stage drug development and discovery
projects- Crystallization Process Development – Improves the crystallization operationyieldo Significantly optimize the solvent residue, particle size distribution, bulk
density, and other powder properties of API products to improve the overall
quality and added value of products- Solid-State Testing and Analysis – XtalPi’s Rational Drug Design and Development
Experimental Center offers a variety of chemical solid state characterization
serviceso Including: X-ray diffractometer (XRD), Thermogravimetric analysis (TGA_,Differential scanning calorimetry (DSC), Dynamic vapor sorption analysis(DS), and Hot stage microscopy (HSM)- Small-Molecule Drug Design –Eugene Consulting Inc.
1602- 111 St. Clair Ave W
Toronto, ONM4V 1N5o XtalPi’s ID4 platform provides accurate predictions on the physiochemicaland pharmaceutical properties of small-molecule candidates for drug design,solid-form selection, and other critical aspects of drug development
o They offer innovative R&D technologies such as, general force fielddevelopment for drug-like molecules, high-accuracy binding affinity
prediction, and AI-based molecule generation, that can accelerate drug
discovery and increase pipeline success rateo XtalPi provides a variety of drug design solutions such as hit identification,
hit-to-lead/lead generation, and lead optimizationo Their methods are capable of generating million of new candidate
compounds for desired targets, accurately predict their properties like thebiological activity, target selectivity, and draggabilityo They help their clients accelerate the small-molecule drug discovery anddevelopment, reduce R&D costs, and improve the overall success rate ofprojects
o They have also developed the cloud-based platform to support their ID4platform▪ Based on this, they provide a variety of automated, efficient, andintelligent drug discovery services
o The company was founded in 2014 by a group of quantum physicists at MITHit Identification Service
o For a specific target, the first step in thedrug discovery process is theidentification of hit compounds
o Small molecules with novel core
structures and reasonable biologicalactivity can be obtained throughmethods such as high-throughput
screening, virtual screening, and de novo
designo XtalPi’s service helps:▪ Generate synthesizable moleculeswith novel core structures andchemical diversity▪ Rapidly filter the compounds
using a wide array of descriptors▪ Rank the compounds, cluster thestructures, and perform basic SAR analysis
Lead Generation Service

Eugene Consulting Inc.
1602- 111 St. Clair Ave WToronto, ONM4V 1N5

o The next step in the drug discovery process is lead generation – also known
as hit-to-lead optimization▪ Starting from the hit compounds emerged from the earlier stage, acombination of scaffold hopping, R-group substitution, structural
simplification, and molecular hybridization can be used to modify thestructures of hits to achieve better potency, selectivity, and drug-likeproperties
o XtalPi’s service helps:▪ Intelligently design derivatives of hits
▪ Rapidly filter compounds using a wide array of descriptors▪ Accurately predict the physiochemical and drug-like properties▪ Accurately predict the binding affinity of newly designed molecules

Lead Optimization Services
o The last step before arriving at a clinical drug candidate is the optimization oflead compounds
o The structures of the drug candidates are modified to fully enhance theirselectivity, physiochemical and ADMET properties, while maintaining their
biological activity
o Eventually, a safe and effective preclinical candidate compounds is obtainedo The traditional lead optimization process usually costs a significant amountof time and resources, no matter whether it is related to the development ofme-too, me-better, or first-in-class drugs
o XtalPi’s service helps:▪ Generate structures of novel drug candidate with similar scaffolds

Eugene Consulting Inc.
1602- 111 St. Clair Ave W
Toronto, ONM4V 1N5▪
▪

-Accurately predict the physiochemical and drug-like properties
Accurately predict the binding affinity of newly designed molecules

Peptide R&D Collaboration – XtalPi AI Research Center (XARC) provides active
peptide generation, prediction, and recommendation solutions that are based on AI<theoretical calculation, and cloud computing, which can effectively improve R&D
efficiency and shorten the peptide drug R&D cycleo The peptide sequence generational module (XARCP Io algorithm) is based on
the deep learning algorithmo Combined with a large-scale databse of peptide sequences and properties,
XARC IO can rapidly generate million of new peptide sequences and cover
the physiochemical properties space of desired peptides
o The machine-learning-based peptide function prediction mode, XARCP, iscombined with expert judgement model, to quickly screen and recommend
candidate peptide sequences
o XARC’s peptide drug design and function prediction services can be used forthe rational design, prediction, and refined multi-dimensional analysis ofvarious types of peptide compounds, including antihypertensive peptides,
HIV inhibitory peptides, neuropeptides, hemolysis peptides, anti-parasitepeptides, anti-cancer peptides, antimicrobial peptides, cell-penetrating
peptides, anti-viral peptides, peptide hormones, the blood-brain barrier
peptides, anti-angiogenic peptides, and toxic peptides.
o With feedback from further experimental results, the model can be optimized
in future iterations for increased screening efficiency

Eugene Consulting Inc.
1602- 111 St. Clair Ave W
Toronto, ONM4V 1N5-Antibody R&D Collaboration – CADD+AI prediction method can assist thedevelopment of antibody drugs, significantly speed up the R&D process, improve thesuccess rate, and reduce the cost and riskCustomized AI Model Development – XtalPi offers correlation analysis between
sequencing data and phenotypes as well as drug-target-disease association analysis
o XtalPi has developed an AI-empowered process optimization method which
is applicable to a variety of scenarios, including synthesis, cell culture, andscreening of crystallization conditionso They also offer deep-learning-based analysis service of experimental results
to get fast results on experimental statistics such as cell count, cell size andshape measurements, and more
o They provide technical consultation and customized system and model
development services so that users can effectively utilized digital andintelligent tools to address their needso XtalPi provides both cloud and local deployment options for different users
to reach an optimum balance between efficiency, cost, and security based on
their needs

Xtalpi raises $318M from Softbank, Tencent, and others
https://www.fiercebiotech.com/medtech/ai-drug-molecule-designer-xtalpi-raises-318mfor-digital-twin-simulation-efforts - September 28, 2020
- Artificial intelligence=based drug molecule designer, XtalPi, has secured a series C
funding round totaling $318.8 milliono The round was co-led by SoftBank’s Vision Fund 2, PICC Capital andMorningside Venture Capitalo Follow-on investments were also made from the company’s previous
backers, Tencent, Sequoia China, China Life and SIG
o This will help XtalPi expand the reach of its AI and cloud computing-powered
platform- By integrating its virtual R&D work with real-world laboratory testing data, thecompany aims to develop a new digital twin simulation system for modeling theactivity of potential new drugs, making it easier for biopharmaceutical companies topick the best candidates for clinical studies- The company states that it plans to take a “three-pronged approach” to expanding
its platform by simultaneously developing its algorithms, drug-like molecule
database, and computing power- Currently, XtalPi’s system incorporates over 100 algorithms to predict theinteractions between molecules and proteins at the atomic level and map out its
pharmacologic properties- By tapping international cloud-computing providers, the company assembles
supercomputing clusters consisting of over a million processing cores

Eugene Consulting Inc.
1602- 111 St. Clair Ave WToronto, ONM4V 1N5-The company technology platform combines quantum physics, AI and cloudcomputing, to improve the efficiency and accuracy of drug research anddevelopment

Microsoft, Illumina, and Twist forms an alliance to make big data small
https://www.fiercebiotech.com/medtech/microsoft-illumina-twist-work-to-make-bigdata-small-weaving-it-into-dna-archives - November 13, 2020
- Microsoft, Illumina, Twist Bioscience, Western Digital among others to establish aroadmap for the industry toward the wider use of DNA data storageo This alliance was announced at the virtual Flash Memory Summit
o The goal of this alliance is to set technology and formatting standards withthe goal of building interoperable commercial systems capable of housing theexponential amounts of data expected to be generated in the future- Their plan is to use the idea that DNA is an incredible molecule that, by its very
nature, provides ultra-high-density storage for thousands of years- To store data in DNA, a file is converted from its binary sequence of ones and zeros
into the four labelled compounds that make up out genomes: A’s, C’s, T’s, and G’s.
o The information is then broken up into short segments of 200 to 300 genetic
bases which are tagged to an index, synthesized and stored- The companies estimate that 10 full-length movies could be written into DNA
molecules and packed to a volume the size of a grain of salt and that this can last fora very long time under the proper conditions in capsules or glass beads- By mirroring biologic processes, DNA data can also be cheaply and quickly
duplicated and read- In a collaboration with University of Washington, Microsoft demonstrated a fully
automated end-to-end system capable of storing and retrieving data from DNAo They have also separately stored 1GB of data in DNA synthesized by Twistand recovered data from it- Twist Bioscience, Illumina, Western Digital and Microsoft will serve as founding
members of the DNA Data Storage Alliance, and are joined by Ansa Biotechnologies;
Catalog; DNA Script; Imec; Iridia; Molecular Assemblies; and the Molecular
Information Systems Lab at the University of Washington—as well as The Claude
Nobs Foundation, which works to preserve audiovisual recordings through theMontreux Jazz Digital Project, alongside the Swiss Federal Institute of Technology’s
locations in Lausanne and Zurich.